Impact and prevention of severe exacerbations of COPD: a review of the evidence

DMG Halpin, M Miravitlles, N Metzdorf… - International journal of …, 2017 - Taylor & Francis
Severe exacerbations of COPD, ie, those leading to hospitalization, have profound clinical
implications for patients and significant economic consequences for society. The prevalence …

Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials

M Bafadhel, S Peterson, MA De Blas… - The Lancet …, 2018 - thelancet.com
Background The peripheral blood eosinophil count might help identify those patients with
chronic obstructive pulmonary disease (COPD) who will experience fewer exacerbations …

Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease …

S Pascoe, N Locantore, MT Dransfield… - The lancet Respiratory …, 2015 - thelancet.com
Background The short-term benefits of inhaled corticosteroids for patients with chronic
obstructive pulmonary disease (COPD) are greater in patients with evidence of eosinophilic …

FULFIL trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease

DA Lipson, H Barnacle, R Birk, N Brealey… - American journal of …, 2017 - atsjournals.org
Rationale: Randomized data comparing triple therapy with dual inhaled corticosteroid
(ICS)/long-acting β2-agonist (LABA) therapy in patients with chronic obstructive pulmonary …

Blood eosinophils and treatment response with triple and dual combination therapy in chronic obstructive pulmonary disease: analysis of the IMPACT trial

S Pascoe, N Barnes, G Brusselle… - The Lancet …, 2019 - thelancet.com
Background Previous studies have highlighted a relationship between reduction in rate of
exacerbations with therapies containing inhaled corticosteroids (ICS) and baseline blood …

Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease

KM Kew, A Seniukovich - Cochrane Database of Systematic …, 2014 - cochranelibrary.com
Background Inhaled corticosteroids (ICS) are anti‐inflammatory drugs that have proven
benefits for people with worsening symptoms of chronic obstructive pulmonary disease …

Inhaled corticosteroids in COPD and the risk of serious pneumonia

S Suissa, V Patenaude, F Lapi, P Ernst - Thorax, 2013 - thorax.bmj.com
Background Inhaled corticosteroids (ICS) are known to increase the risk of pneumonia in
patients with chronic obstructive pulmonary disease (COPD). It is unclear whether the risk of …

Prevention of acute exacerbations of COPD: American college of chest physicians and Canadian thoracic society guideline

GJ Criner, J Bourbeau, RL Diekemper, DR Ouellette… - Chest, 2015 - Elsevier
BACKGROUND: COPD is a major cause of morbidity and mortality in the United States as
well as throughout the rest of the world. An exacerbation of COPD (periodic escalations of …

Systematic review on long-term adverse effects of inhaled corticosteroids in the treatment of COPD

M Miravitlles, A Auladell-Rispau… - European …, 2021 - Eur Respiratory Soc
Inhaled corticosteroids (ICSs) are indicated for the prevention of exacerbations in COPD;
however, a significant proportion of patients at low risk of exacerbations are treated with …

Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only for prevention of exacerbations of COPD: two replicate double-blind, parallel-group …

MT Dransfield, J Bourbeau, PW Jones… - The Lancet …, 2013 - thelancet.com
Background Whether the combination of a once-daily inhaled corticosteroid with a once-
daily longacting β 2 agonist is more protective than a once-daily longacting β 2 agonist …